Piper Jaffray analyst Sean Wieland raised his price target for Teladoc to $88 from $84 following the company’s analyst day. Management committed to 20%-30% organic revenue growth, positive free cash flow in 2019, and inched up 2018 guidance on greater revenue per client, Wieland tells investors in a research note. He believes the Advance Medical acquisition should drive international share gains and reiterates an Overweight rating on Teladoc shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.